Found 4 articles for: "dermatology life quality index"
Clascoterone Cream 1% is Safe and Effective for Papulopustular Rosacea: A Phase 2 Clinical Trial
August 2026 | Volume 25 | Issue 8 | Original Article | 701 | Copyright © August 2026
Background: Papulopustular rosacea (PPR) is a chronic inflammatory facial dermatosis with a need for well-tolerated and effective topical therapies. Clascoterone cream 1% is an a...
Read MoreEvaluating the Safety and Efficacy of Sirolimus Topical Gel 0.2% to Treat Acanthosis Nigricans
July 2026 | Volume 25 | Issue 7 | Original Article | 615 | Copyright © July 2026
Background: There are currently no FDA-approved pharmacologic treatments for acanthosis nigricans (AN), a common dermatologic condition characterized by hyperpigmented, velvety p...
Read MoreEfficacy and Safety of Clascoterone Cream 1% and Adapalene Gel 0.3% in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 545 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved for the treatment of acne vulgaris in patients ≥12 years of age. The American Academy of De...
Read MoreAn Investigator-Developed Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color
April 2026 | Volume 25 | Issue 4 | Original Article | 330 | Copyright © April 2026
Background: There is an unmet demand for a post-inflammatory hyperpigmentation (PIH) treatment and prevention that is not only effective and accessible, but also safe to use in d...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
